nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—attention deficit hyperactivity disorder—Clonidine—glaucoma	0.507	1	CpDpCtD
Amphetamine—SLC22A3—Clonidine—glaucoma	0.0718	0.233	CbGbCtD
Amphetamine—CYP2A6—Pilocarpine—glaucoma	0.0694	0.226	CbGbCtD
Amphetamine—SLC22A5—Clonidine—glaucoma	0.0446	0.145	CbGbCtD
Amphetamine—SLC6A2—Clonidine—glaucoma	0.0355	0.116	CbGbCtD
Amphetamine—CYP2D6—Carteolol—glaucoma	0.0288	0.0937	CbGbCtD
Amphetamine—CYP2D6—Betaxolol—glaucoma	0.0194	0.0633	CbGbCtD
Amphetamine—CYP2D6—Methazolamide—glaucoma	0.0147	0.0479	CbGbCtD
Amphetamine—CYP2D6—Timolol—glaucoma	0.0125	0.0408	CbGbCtD
Amphetamine—CYP2D6—Clonidine—glaucoma	0.0107	0.0347	CbGbCtD
Amphetamine—Lacosamide—CA1—glaucoma	0.000493	0.446	CrCbGaD
Amphetamine—Lacosamide—CA2—glaucoma	0.000374	0.338	CrCbGaD
Amphetamine—Pseudoephedrine—TNF—glaucoma	0.000238	0.216	CrCbGaD
Amphetamine—Nausea—Carteolol—glaucoma	0.000229	0.00174	CcSEcCtD
Amphetamine—Headache—Levobunolol—glaucoma	0.000229	0.00173	CcSEcCtD
Amphetamine—Depression—Betaxolol—glaucoma	0.000228	0.00173	CcSEcCtD
Amphetamine—Chest pain—Brinzolamide—glaucoma	0.000227	0.00173	CcSEcCtD
Amphetamine—Palpitations—Pilocarpine—glaucoma	0.000227	0.00172	CcSEcCtD
Amphetamine—Tachycardia—Brimonidine—glaucoma	0.000227	0.00172	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000226	0.00172	CcSEcCtD
Amphetamine—Dry mouth—Dorzolamide—glaucoma	0.000226	0.00172	CcSEcCtD
Amphetamine—Nausea—Diclofenamide—glaucoma	0.000226	0.00171	CcSEcCtD
Amphetamine—Dry mouth—Travoprost—glaucoma	0.000225	0.00171	CcSEcCtD
Amphetamine—Acute coronary syndrome—Betaxolol—glaucoma	0.000225	0.00171	CcSEcCtD
Amphetamine—Myocardial infarction—Betaxolol—glaucoma	0.000224	0.0017	CcSEcCtD
Amphetamine—Dizziness—Latanoprost—glaucoma	0.000224	0.0017	CcSEcCtD
Amphetamine—Dry mouth—Brinzolamide—glaucoma	0.000222	0.00169	CcSEcCtD
Amphetamine—Vomiting—Methazolamide—glaucoma	0.000222	0.00169	CcSEcCtD
Amphetamine—Anaphylactic shock—Dorzolamide—glaucoma	0.000222	0.00168	CcSEcCtD
Amphetamine—Hypertension—Pilocarpine—glaucoma	0.000222	0.00168	CcSEcCtD
Amphetamine—Gastrointestinal pain—Apraclonidine—glaucoma	0.000221	0.00168	CcSEcCtD
Amphetamine—Abdominal pain upper—Timolol—glaucoma	0.000221	0.00168	CcSEcCtD
Amphetamine—Rash—Methazolamide—glaucoma	0.00022	0.00167	CcSEcCtD
Amphetamine—Dermatitis—Methazolamide—glaucoma	0.00022	0.00167	CcSEcCtD
Amphetamine—Nausea—Carbachol—glaucoma	0.00022	0.00167	CcSEcCtD
Amphetamine—Infection—Travoprost—glaucoma	0.000219	0.00166	CcSEcCtD
Amphetamine—Sweating—Betaxolol—glaucoma	0.000219	0.00166	CcSEcCtD
Amphetamine—Headache—Methazolamide—glaucoma	0.000219	0.00166	CcSEcCtD
Amphetamine—Chest pain—Pilocarpine—glaucoma	0.000219	0.00166	CcSEcCtD
Amphetamine—Anxiety—Pilocarpine—glaucoma	0.000218	0.00165	CcSEcCtD
Amphetamine—Nausea—Levobunolol—glaucoma	0.000217	0.00164	CcSEcCtD
Amphetamine—Infection—Brinzolamide—glaucoma	0.000217	0.00164	CcSEcCtD
Amphetamine—Tachycardia—Travoprost—glaucoma	0.000216	0.00163	CcSEcCtD
Amphetamine—Somnolence—Acetazolamide—glaucoma	0.000215	0.00163	CcSEcCtD
Amphetamine—Hyperhidrosis—Dorzolamide—glaucoma	0.000214	0.00163	CcSEcCtD
Amphetamine—Abdominal pain—Apraclonidine—glaucoma	0.000214	0.00162	CcSEcCtD
Amphetamine—Rash—Latanoprost—glaucoma	0.000213	0.00162	CcSEcCtD
Amphetamine—Dermatitis—Latanoprost—glaucoma	0.000213	0.00162	CcSEcCtD
Amphetamine—Dyspepsia—Acetazolamide—glaucoma	0.000213	0.00162	CcSEcCtD
Amphetamine—Tachycardia—Brinzolamide—glaucoma	0.000213	0.00161	CcSEcCtD
Amphetamine—Headache—Latanoprost—glaucoma	0.000212	0.00161	CcSEcCtD
Amphetamine—Anorexia—Dorzolamide—glaucoma	0.000211	0.0016	CcSEcCtD
Amphetamine—Decreased appetite—Acetazolamide—glaucoma	0.00021	0.0016	CcSEcCtD
Amphetamine—Insomnia—Brimonidine—glaucoma	0.00021	0.00159	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000209	0.00158	CcSEcCtD
Amphetamine—Fatigue—Acetazolamide—glaucoma	0.000209	0.00158	CcSEcCtD
Amphetamine—Infection—Pilocarpine—glaucoma	0.000208	0.00158	CcSEcCtD
Amphetamine—Nausea—Methazolamide—glaucoma	0.000208	0.00157	CcSEcCtD
Amphetamine—Dyspnoea—Brimonidine—glaucoma	0.000207	0.00157	CcSEcCtD
Amphetamine—Somnolence—Brimonidine—glaucoma	0.000206	0.00157	CcSEcCtD
Amphetamine—Tachycardia—Pilocarpine—glaucoma	0.000205	0.00155	CcSEcCtD
Amphetamine—Dyspepsia—Brimonidine—glaucoma	0.000204	0.00155	CcSEcCtD
Amphetamine—Hyperhidrosis—Pilocarpine—glaucoma	0.000203	0.00154	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000203	0.00383	CbGpPWpGaD
Amphetamine—Tension—Clonidine—glaucoma	0.000201	0.00153	CcSEcCtD
Amphetamine—Insomnia—Dorzolamide—glaucoma	0.000201	0.00152	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Brimonidine—glaucoma	0.000201	0.00152	CcSEcCtD
Amphetamine—Fatigue—Brimonidine—glaucoma	0.0002	0.00152	CcSEcCtD
Amphetamine—Anorexia—Pilocarpine—glaucoma	0.0002	0.00152	CcSEcCtD
Amphetamine—Hypersensitivity—Apraclonidine—glaucoma	0.000199	0.00151	CcSEcCtD
Amphetamine—Nervousness—Clonidine—glaucoma	0.000199	0.00151	CcSEcCtD
Amphetamine—Dyspnoea—Dorzolamide—glaucoma	0.000198	0.0015	CcSEcCtD
Amphetamine—Insomnia—Brinzolamide—glaucoma	0.000197	0.0015	CcSEcCtD
Amphetamine—Somnolence—Dorzolamide—glaucoma	0.000197	0.0015	CcSEcCtD
Amphetamine—Dyspnoea—Travoprost—glaucoma	0.000197	0.00149	CcSEcCtD
Amphetamine—Dyspepsia—Dorzolamide—glaucoma	0.000195	0.00148	CcSEcCtD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000195	0.00369	CbGpPWpGaD
Amphetamine—Dyspnoea—Brinzolamide—glaucoma	0.000194	0.00147	CcSEcCtD
Amphetamine—Dyspepsia—Travoprost—glaucoma	0.000194	0.00147	CcSEcCtD
Amphetamine—Asthenia—Apraclonidine—glaucoma	0.000194	0.00147	CcSEcCtD
Amphetamine—Somnolence—Brinzolamide—glaucoma	0.000194	0.00147	CcSEcCtD
Amphetamine—Decreased appetite—Dorzolamide—glaucoma	0.000193	0.00146	CcSEcCtD
Amphetamine—Erectile dysfunction—Timolol—glaucoma	0.000193	0.00146	CcSEcCtD
Amphetamine—Urticaria—Acetazolamide—glaucoma	0.000192	0.00146	CcSEcCtD
Amphetamine—Tremor—Clonidine—glaucoma	0.000192	0.00146	CcSEcCtD
Amphetamine—Dyspepsia—Brinzolamide—glaucoma	0.000192	0.00146	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A13—glaucoma	0.000192	0.00363	CbGpPWpGaD
Amphetamine—Body temperature increased—Acetazolamide—glaucoma	0.000191	0.00145	CcSEcCtD
Amphetamine—Fatigue—Dorzolamide—glaucoma	0.000191	0.00145	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Travoprost—glaucoma	0.000191	0.00145	CcSEcCtD
Amphetamine—CYP2D6—Tamoxifen metabolism—CYP1B1—glaucoma	0.000191	0.00361	CbGpPWpGaD
Amphetamine—Fatigue—Travoprost—glaucoma	0.00019	0.00144	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—glaucoma	0.00019	0.0036	CbGpPWpGaD
Amphetamine—Insomnia—Pilocarpine—glaucoma	0.00019	0.00144	CcSEcCtD
Amphetamine—Decreased appetite—Brinzolamide—glaucoma	0.00019	0.00144	CcSEcCtD
Amphetamine—Weight decreased—Timolol—glaucoma	0.000189	0.00144	CcSEcCtD
Amphetamine—Constipation—Travoprost—glaucoma	0.000189	0.00143	CcSEcCtD
Amphetamine—Agitation—Clonidine—glaucoma	0.000188	0.00143	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000188	0.00143	CcSEcCtD
Amphetamine—Asthenia—Bimatoprost—glaucoma	0.000188	0.00143	CcSEcCtD
Amphetamine—Fatigue—Brinzolamide—glaucoma	0.000188	0.00143	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—OPN4—glaucoma	0.000188	0.00355	CbGpPWpGaD
Amphetamine—Angioedema—Clonidine—glaucoma	0.000187	0.00142	CcSEcCtD
Amphetamine—Dyspnoea—Pilocarpine—glaucoma	0.000187	0.00142	CcSEcCtD
Amphetamine—Somnolence—Pilocarpine—glaucoma	0.000186	0.00141	CcSEcCtD
Amphetamine—Depression—Timolol—glaucoma	0.000186	0.00141	CcSEcCtD
Amphetamine—Diarrhoea—Apraclonidine—glaucoma	0.000185	0.0014	CcSEcCtD
Amphetamine—Dyspepsia—Pilocarpine—glaucoma	0.000185	0.0014	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—TXN—glaucoma	0.000183	0.00347	CbGpPWpGaD
Amphetamine—SLC6A3—Alpha-synuclein signaling—BAD—glaucoma	0.000183	0.00346	CbGpPWpGaD
Amphetamine—Decreased appetite—Pilocarpine—glaucoma	0.000182	0.00138	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dorzolamide—glaucoma	0.000181	0.00138	CcSEcCtD
Amphetamine—Palpitations—Clonidine—glaucoma	0.000181	0.00137	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000181	0.00343	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000181	0.00137	CcSEcCtD
Amphetamine—Gastrointestinal pain—Travoprost—glaucoma	0.000181	0.00137	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.00018	0.0034	CbGpPWpGaD
Amphetamine—Constipation—Pilocarpine—glaucoma	0.000179	0.00136	CcSEcCtD
Amphetamine—Sweating—Timolol—glaucoma	0.000179	0.00136	CcSEcCtD
Amphetamine—Dizziness—Apraclonidine—glaucoma	0.000179	0.00136	CcSEcCtD
Amphetamine—Urticaria—Dorzolamide—glaucoma	0.000176	0.00134	CcSEcCtD
Amphetamine—Body temperature increased—Dorzolamide—glaucoma	0.000175	0.00133	CcSEcCtD
Amphetamine—Abdominal pain—Dorzolamide—glaucoma	0.000175	0.00133	CcSEcCtD
Amphetamine—Tension—Betaxolol—glaucoma	0.000175	0.00133	CcSEcCtD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—PEX19—glaucoma	0.000175	0.00332	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—PEX19—glaucoma	0.000175	0.0033	CbGpPWpGaD
Amphetamine—Chest pain—Clonidine—glaucoma	0.000175	0.00132	CcSEcCtD
Amphetamine—Abdominal pain—Travoprost—glaucoma	0.000175	0.00132	CcSEcCtD
Amphetamine—Anxiety—Clonidine—glaucoma	0.000174	0.00132	CcSEcCtD
Amphetamine—Asthenia—Acetazolamide—glaucoma	0.000174	0.00132	CcSEcCtD
Amphetamine—Dizziness—Bimatoprost—glaucoma	0.000173	0.00132	CcSEcCtD
Amphetamine—Nervousness—Betaxolol—glaucoma	0.000173	0.00132	CcSEcCtD
Amphetamine—Urticaria—Brinzolamide—glaucoma	0.000173	0.00131	CcSEcCtD
Amphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000173	0.00327	CbGpPWpGaD
Amphetamine—Vomiting—Apraclonidine—glaucoma	0.000172	0.0013	CcSEcCtD
Amphetamine—Gastrointestinal pain—Pilocarpine—glaucoma	0.000171	0.0013	CcSEcCtD
Amphetamine—Hypersensitivity—Brimonidine—glaucoma	0.000171	0.0013	CcSEcCtD
Amphetamine—Dry mouth—Clonidine—glaucoma	0.000171	0.0013	CcSEcCtD
Amphetamine—Dermatitis—Apraclonidine—glaucoma	0.00017	0.00129	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—OPN4—glaucoma	0.00017	0.00322	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A13—glaucoma	0.00017	0.00322	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC6A13—glaucoma	0.00017	0.00321	CbGpPWpGaD
Amphetamine—Headache—Apraclonidine—glaucoma	0.000169	0.00129	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—PTGFR—glaucoma	0.000169	0.0032	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000168	0.00318	CbGpPWpGaD
Amphetamine—Tremor—Betaxolol—glaucoma	0.000167	0.00127	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—MTHFR—glaucoma	0.000167	0.00316	CbGpPWpGaD
Amphetamine—Asthenia—Brimonidine—glaucoma	0.000167	0.00126	CcSEcCtD
Amphetamine—Infection—Clonidine—glaucoma	0.000166	0.00126	CcSEcCtD
Amphetamine—Abdominal pain—Pilocarpine—glaucoma	0.000166	0.00126	CcSEcCtD
Amphetamine—Body temperature increased—Pilocarpine—glaucoma	0.000166	0.00126	CcSEcCtD
Amphetamine—Diarrhoea—Acetazolamide—glaucoma	0.000166	0.00126	CcSEcCtD
Amphetamine—Rash—Bimatoprost—glaucoma	0.000165	0.00125	CcSEcCtD
Amphetamine—Dermatitis—Bimatoprost—glaucoma	0.000165	0.00125	CcSEcCtD
Amphetamine—Headache—Bimatoprost—glaucoma	0.000164	0.00125	CcSEcCtD
Amphetamine—Hypersensitivity—Dorzolamide—glaucoma	0.000163	0.00124	CcSEcCtD
Amphetamine—Tachycardia—Clonidine—glaucoma	0.000163	0.00124	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—SLC6A1—glaucoma	0.000163	0.00309	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—GSTT1—glaucoma	0.000163	0.00308	CbGpPWpGaD
Amphetamine—Hypersensitivity—Travoprost—glaucoma	0.000163	0.00123	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000162	0.00307	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Clonidine—glaucoma	0.000162	0.00123	CcSEcCtD
Amphetamine—Nausea—Apraclonidine—glaucoma	0.000161	0.00122	CcSEcCtD
Amphetamine—Hypersensitivity—Brinzolamide—glaucoma	0.000161	0.00122	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000161	0.00304	CbGpPWpGaD
Amphetamine—Dizziness—Acetazolamide—glaucoma	0.00016	0.00121	CcSEcCtD
Amphetamine—Anorexia—Clonidine—glaucoma	0.00016	0.00121	CcSEcCtD
Amphetamine—Asthenia—Dorzolamide—glaucoma	0.000159	0.00121	CcSEcCtD
Amphetamine—Asthenia—Travoprost—glaucoma	0.000158	0.0012	CcSEcCtD
Amphetamine—Palpitations—Betaxolol—glaucoma	0.000158	0.0012	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—TXN—glaucoma	0.000158	0.00298	CbGpPWpGaD
Amphetamine—Asthenia—Brinzolamide—glaucoma	0.000156	0.00119	CcSEcCtD
Amphetamine—Nausea—Bimatoprost—glaucoma	0.000156	0.00118	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000155	0.00294	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000155	0.00293	CbGpPWpGaD
Amphetamine—Hypersensitivity—Pilocarpine—glaucoma	0.000154	0.00117	CcSEcCtD
Amphetamine—Vomiting—Acetazolamide—glaucoma	0.000154	0.00117	CcSEcCtD
Amphetamine—Dizziness—Brimonidine—glaucoma	0.000154	0.00116	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PTGFR—glaucoma	0.000153	0.0029	CbGpPWpGaD
Amphetamine—Chest pain—Betaxolol—glaucoma	0.000152	0.00115	CcSEcCtD
Amphetamine—Diarrhoea—Dorzolamide—glaucoma	0.000152	0.00115	CcSEcCtD
Amphetamine—Headache—Acetazolamide—glaucoma	0.000152	0.00115	CcSEcCtD
Amphetamine—Anxiety—Betaxolol—glaucoma	0.000151	0.00115	CcSEcCtD
Amphetamine—Insomnia—Clonidine—glaucoma	0.000151	0.00115	CcSEcCtD
Amphetamine—Diarrhoea—Travoprost—glaucoma	0.000151	0.00115	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SMO—glaucoma	0.000151	0.00285	CbGpPWpGaD
Amphetamine—Asthenia—Pilocarpine—glaucoma	0.00015	0.00114	CcSEcCtD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.00015	0.00284	CbGpPWpGaD
Amphetamine—Dyspnoea—Clonidine—glaucoma	0.000149	0.00113	CcSEcCtD
Amphetamine—Diarrhoea—Brinzolamide—glaucoma	0.000149	0.00113	CcSEcCtD
Amphetamine—Somnolence—Clonidine—glaucoma	0.000149	0.00113	CcSEcCtD
Amphetamine—Dry mouth—Betaxolol—glaucoma	0.000149	0.00113	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000147	0.00279	CbGpPWpGaD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000147	0.00278	CbGpPWpGaD
Amphetamine—Dizziness—Dorzolamide—glaucoma	0.000147	0.00111	CcSEcCtD
Amphetamine—Rash—Brimonidine—glaucoma	0.000146	0.00111	CcSEcCtD
Amphetamine—Dermatitis—Brimonidine—glaucoma	0.000146	0.00111	CcSEcCtD
Amphetamine—Dizziness—Travoprost—glaucoma	0.000146	0.00111	CcSEcCtD
Amphetamine—Headache—Brimonidine—glaucoma	0.000146	0.0011	CcSEcCtD
Amphetamine—Decreased appetite—Clonidine—glaucoma	0.000146	0.0011	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—LRP12—glaucoma	0.000145	0.00275	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—OPN4—glaucoma	0.000145	0.00274	CbGpPWpGaD
Amphetamine—Infection—Betaxolol—glaucoma	0.000145	0.0011	CcSEcCtD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000145	0.00274	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Clonidine—glaucoma	0.000145	0.0011	CcSEcCtD
Amphetamine—Fatigue—Clonidine—glaucoma	0.000144	0.00109	CcSEcCtD
Amphetamine—Dizziness—Brinzolamide—glaucoma	0.000144	0.00109	CcSEcCtD
Amphetamine—Nausea—Acetazolamide—glaucoma	0.000144	0.00109	CcSEcCtD
Amphetamine—Diarrhoea—Pilocarpine—glaucoma	0.000143	0.00109	CcSEcCtD
Amphetamine—Tension—Timolol—glaucoma	0.000143	0.00109	CcSEcCtD
Amphetamine—Constipation—Clonidine—glaucoma	0.000143	0.00109	CcSEcCtD
Amphetamine—Tachycardia—Betaxolol—glaucoma	0.000142	0.00108	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A13—glaucoma	0.000142	0.00269	CbGpPWpGaD
Amphetamine—Nervousness—Timolol—glaucoma	0.000142	0.00107	CcSEcCtD
Amphetamine—Vomiting—Dorzolamide—glaucoma	0.000141	0.00107	CcSEcCtD
Amphetamine—Hyperhidrosis—Betaxolol—glaucoma	0.000141	0.00107	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A1—glaucoma	0.00014	0.00266	CbGpPWpGaD
Amphetamine—Rash—Dorzolamide—glaucoma	0.00014	0.00106	CcSEcCtD
Amphetamine—Dermatitis—Dorzolamide—glaucoma	0.00014	0.00106	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—TXN—glaucoma	0.00014	0.00264	CbGpPWpGaD
Amphetamine—Rash—Travoprost—glaucoma	0.000139	0.00106	CcSEcCtD
Amphetamine—Dermatitis—Travoprost—glaucoma	0.000139	0.00106	CcSEcCtD
Amphetamine—Headache—Dorzolamide—glaucoma	0.000139	0.00105	CcSEcCtD
Amphetamine—Anorexia—Betaxolol—glaucoma	0.000139	0.00105	CcSEcCtD
Amphetamine—Vomiting—Brinzolamide—glaucoma	0.000139	0.00105	CcSEcCtD
Amphetamine—Dizziness—Pilocarpine—glaucoma	0.000139	0.00105	CcSEcCtD
Amphetamine—Headache—Travoprost—glaucoma	0.000138	0.00105	CcSEcCtD
Amphetamine—Nausea—Brimonidine—glaucoma	0.000138	0.00105	CcSEcCtD
Amphetamine—Rash—Brinzolamide—glaucoma	0.000138	0.00104	CcSEcCtD
Amphetamine—Dermatitis—Brinzolamide—glaucoma	0.000137	0.00104	CcSEcCtD
Amphetamine—Gastrointestinal pain—Clonidine—glaucoma	0.000137	0.00104	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000137	0.00259	CbGpPWpGaD
Amphetamine—Headache—Brinzolamide—glaucoma	0.000137	0.00104	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000136	0.00258	CbGpPWpGaD
Amphetamine—Angioedema—Timolol—glaucoma	0.000133	0.00101	CcSEcCtD
Amphetamine—Vomiting—Pilocarpine—glaucoma	0.000133	0.00101	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—TGFB2—glaucoma	0.000133	0.00252	CbGpPWpGaD
Amphetamine—Urticaria—Clonidine—glaucoma	0.000133	0.00101	CcSEcCtD
Amphetamine—Abdominal pain—Clonidine—glaucoma	0.000132	0.001	CcSEcCtD
Amphetamine—Body temperature increased—Clonidine—glaucoma	0.000132	0.001	CcSEcCtD
Amphetamine—Rash—Pilocarpine—glaucoma	0.000132	0.001	CcSEcCtD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000132	0.0025	CbGpPWpGaD
Amphetamine—Dermatitis—Pilocarpine—glaucoma	0.000132	0.001	CcSEcCtD
Amphetamine—Insomnia—Betaxolol—glaucoma	0.000132	0.001	CcSEcCtD
Amphetamine—Nausea—Dorzolamide—glaucoma	0.000132	0.000999	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000132	0.00249	CbGpPWpGaD
Amphetamine—Headache—Pilocarpine—glaucoma	0.000131	0.000996	CcSEcCtD
Amphetamine—Nausea—Travoprost—glaucoma	0.000131	0.000995	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.00013	0.00247	CbGpPWpGaD
Amphetamine—Dyspnoea—Betaxolol—glaucoma	0.00013	0.000985	CcSEcCtD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00013	0.00245	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—CYP1B1—glaucoma	0.00013	0.00245	CbGpPWpGaD
Amphetamine—Nausea—Brinzolamide—glaucoma	0.00013	0.000982	CcSEcCtD
Amphetamine—Palpitations—Timolol—glaucoma	0.000129	0.000978	CcSEcCtD
Amphetamine—Dyspepsia—Betaxolol—glaucoma	0.000128	0.000973	CcSEcCtD
Amphetamine—Decreased appetite—Betaxolol—glaucoma	0.000127	0.000961	CcSEcCtD
Amphetamine—Hypertension—Timolol—glaucoma	0.000126	0.000955	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Betaxolol—glaucoma	0.000126	0.000954	CcSEcCtD
Amphetamine—Fatigue—Betaxolol—glaucoma	0.000126	0.000953	CcSEcCtD
Amphetamine—Constipation—Betaxolol—glaucoma	0.000125	0.000945	CcSEcCtD
Amphetamine—Nausea—Pilocarpine—glaucoma	0.000125	0.000944	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A1—glaucoma	0.000124	0.00235	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC6A1—glaucoma	0.000124	0.00235	CbGpPWpGaD
Amphetamine—Chest pain—Timolol—glaucoma	0.000124	0.000942	CcSEcCtD
Amphetamine—Anxiety—Timolol—glaucoma	0.000124	0.000939	CcSEcCtD
Amphetamine—Hypersensitivity—Clonidine—glaucoma	0.000123	0.000935	CcSEcCtD
Amphetamine—Dry mouth—Timolol—glaucoma	0.000121	0.000921	CcSEcCtD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000121	0.00229	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—PEX19—glaucoma	0.000121	0.00229	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.00012	0.00228	CbGpPWpGaD
Amphetamine—Asthenia—Clonidine—glaucoma	0.00012	0.000911	CcSEcCtD
Amphetamine—Anaphylactic shock—Timolol—glaucoma	0.000119	0.000903	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—EDN1—glaucoma	0.000119	0.00225	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000119	0.00225	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000119	0.00225	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000118	0.00224	CbGpPWpGaD
Amphetamine—Infection—Timolol—glaucoma	0.000118	0.000897	CcSEcCtD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000118	0.00223	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—TXN—glaucoma	0.000117	0.00221	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—TNF—glaucoma	0.000116	0.00219	CbGpPWpGaD
Amphetamine—Urticaria—Betaxolol—glaucoma	0.000116	0.000878	CcSEcCtD
Amphetamine—Body temperature increased—Betaxolol—glaucoma	0.000115	0.000874	CcSEcCtD
Amphetamine—Hyperhidrosis—Timolol—glaucoma	0.000115	0.000873	CcSEcCtD
Amphetamine—Diarrhoea—Clonidine—glaucoma	0.000115	0.000869	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—TGFB2—glaucoma	0.000114	0.00217	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CA5A—glaucoma	0.000114	0.00216	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NARFL—glaucoma	0.000114	0.00216	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000114	0.00216	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000114	0.00215	CbGpPWpGaD
Amphetamine—Anorexia—Timolol—glaucoma	0.000113	0.000861	CcSEcCtD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000113	0.00215	CbGpPWpGaD
Amphetamine—Dizziness—Clonidine—glaucoma	0.000111	0.000839	CcSEcCtD
Amphetamine—Insomnia—Timolol—glaucoma	0.000108	0.000817	CcSEcCtD
Amphetamine—Hypersensitivity—Betaxolol—glaucoma	0.000107	0.000814	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000107	0.00203	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000107	0.00202	CbGpPWpGaD
Amphetamine—Vomiting—Clonidine—glaucoma	0.000106	0.000807	CcSEcCtD
Amphetamine—Dyspnoea—Timolol—glaucoma	0.000106	0.000805	CcSEcCtD
Amphetamine—Somnolence—Timolol—glaucoma	0.000106	0.000803	CcSEcCtD
Amphetamine—Rash—Clonidine—glaucoma	0.000106	0.0008	CcSEcCtD
Amphetamine—Dermatitis—Clonidine—glaucoma	0.000105	0.0008	CcSEcCtD
Amphetamine—Headache—Clonidine—glaucoma	0.000105	0.000795	CcSEcCtD
Amphetamine—Dyspepsia—Timolol—glaucoma	0.000105	0.000795	CcSEcCtD
Amphetamine—Asthenia—Betaxolol—glaucoma	0.000105	0.000793	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A1—glaucoma	0.000104	0.00197	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—GSTM1—glaucoma	0.000104	0.00196	CbGpPWpGaD
Amphetamine—Decreased appetite—Timolol—glaucoma	0.000103	0.000785	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Timolol—glaucoma	0.000103	0.000779	CcSEcCtD
Amphetamine—Fatigue—Timolol—glaucoma	0.000103	0.000778	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000102	0.00192	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—TGFB2—glaucoma	0.000101	0.00192	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—SLC6A13—glaucoma	0.000101	0.00192	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—OPN4—glaucoma	0.000101	0.0019	CbGpPWpGaD
Amphetamine—SLC6A2—Monoamine Transport—TNF—glaucoma	9.97e-05	0.00189	CbGpPWpGaD
Amphetamine—Diarrhoea—Betaxolol—glaucoma	9.97e-05	0.000756	CcSEcCtD
Amphetamine—Nausea—Clonidine—glaucoma	9.94e-05	0.000754	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—EDN1—glaucoma	9.93e-05	0.00188	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Timolol—glaucoma	9.74e-05	0.000738	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—APOE—glaucoma	9.68e-05	0.00183	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—glaucoma	9.67e-05	0.00183	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NARFL—glaucoma	9.65e-05	0.00183	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CA5A—glaucoma	9.65e-05	0.00183	CbGpPWpGaD
Amphetamine—Dizziness—Betaxolol—glaucoma	9.64e-05	0.000731	CcSEcCtD
Amphetamine—Urticaria—Timolol—glaucoma	9.46e-05	0.000717	CcSEcCtD
Amphetamine—Abdominal pain—Timolol—glaucoma	9.41e-05	0.000714	CcSEcCtD
Amphetamine—Body temperature increased—Timolol—glaucoma	9.41e-05	0.000714	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—HEYL—glaucoma	9.35e-05	0.00177	CbGpPWpGaD
Amphetamine—Vomiting—Betaxolol—glaucoma	9.27e-05	0.000703	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	9.21e-05	0.00174	CbGpPWpGaD
Amphetamine—Rash—Betaxolol—glaucoma	9.19e-05	0.000697	CcSEcCtD
Amphetamine—Dermatitis—Betaxolol—glaucoma	9.18e-05	0.000696	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	9.15e-05	0.00173	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	9.13e-05	0.00173	CbGpPWpGaD
Amphetamine—Headache—Betaxolol—glaucoma	9.13e-05	0.000692	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—PTGFR—glaucoma	9.06e-05	0.00171	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—GSTM1—glaucoma	9.05e-05	0.00171	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—glaucoma	8.99e-05	0.0017	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	8.85e-05	0.00167	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—glaucoma	8.84e-05	0.00167	CbGpPWpGaD
Amphetamine—Hypersensitivity—Timolol—glaucoma	8.77e-05	0.000665	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—C3—glaucoma	8.68e-05	0.00164	CbGpPWpGaD
Amphetamine—Nausea—Betaxolol—glaucoma	8.66e-05	0.000656	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL1A—glaucoma	8.63e-05	0.00163	CbGpPWpGaD
Amphetamine—Asthenia—Timolol—glaucoma	8.54e-05	0.000648	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—TGFB2—glaucoma	8.47e-05	0.0016	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NGFR—glaucoma	8.44e-05	0.0016	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	8.23e-05	0.00156	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC4A4—glaucoma	8.16e-05	0.00154	CbGpPWpGaD
Amphetamine—Diarrhoea—Timolol—glaucoma	8.15e-05	0.000618	CcSEcCtD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—glaucoma	8.12e-05	0.00154	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NTRK1—glaucoma	8.02e-05	0.00152	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NGF—glaucoma	7.98e-05	0.00151	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NR3C1—glaucoma	7.94e-05	0.0015	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTT1—glaucoma	7.93e-05	0.0015	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A13—glaucoma	7.9e-05	0.00149	CbGpPWpGaD
Amphetamine—Dizziness—Timolol—glaucoma	7.87e-05	0.000597	CcSEcCtD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A13—glaucoma	7.87e-05	0.00149	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—glaucoma	7.84e-05	0.00148	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSTM1—glaucoma	7.78e-05	0.00147	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—OPN4—glaucoma	7.74e-05	0.00146	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SMO—glaucoma	7.73e-05	0.00146	CbGpPWpGaD
Amphetamine—Vomiting—Timolol—glaucoma	7.57e-05	0.000574	CcSEcCtD
Amphetamine—Rash—Timolol—glaucoma	7.51e-05	0.000569	CcSEcCtD
Amphetamine—Dermatitis—Timolol—glaucoma	7.5e-05	0.000569	CcSEcCtD
Amphetamine—Headache—Timolol—glaucoma	7.46e-05	0.000566	CcSEcCtD
Amphetamine—SLC6A3—Neuronal System—SLC6A1—glaucoma	7.41e-05	0.0014	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RPTOR—glaucoma	7.09e-05	0.00134	CbGpPWpGaD
Amphetamine—Nausea—Timolol—glaucoma	7.07e-05	0.000536	CcSEcCtD
Amphetamine—DRD2—GPCR ligand binding—PTGFR—glaucoma	6.97e-05	0.00132	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GSTM1—glaucoma	6.89e-05	0.0013	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NCK2—glaucoma	6.87e-05	0.0013	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	6.68e-05	0.00126	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	6.67e-05	0.00126	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—glaucoma	6.35e-05	0.0012	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—CYP1B1—glaucoma	6.32e-05	0.0012	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—FAS—glaucoma	6.28e-05	0.00119	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	6.14e-05	0.00116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HDAC9—glaucoma	5.84e-05	0.0011	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.78e-05	0.00109	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.76e-05	0.00109	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSTM1—glaucoma	5.76e-05	0.00109	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—EDN1—glaucoma	5.61e-05	0.00106	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CA1—glaucoma	5.57e-05	0.00105	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CA5A—glaucoma	5.56e-05	0.00105	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NARFL—glaucoma	5.56e-05	0.00105	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A13—glaucoma	5.44e-05	0.00103	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CTSA—glaucoma	5.39e-05	0.00102	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NGFR—glaucoma	5.16e-05	0.000977	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EDN1—glaucoma	5.1e-05	0.000965	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CA2—glaucoma	5.09e-05	0.000964	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTM1—glaucoma	5.05e-05	0.000956	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—C3—glaucoma	4.9e-05	0.000928	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NTRK1—glaucoma	4.9e-05	0.000928	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CA1—glaucoma	4.71e-05	0.000892	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMO—glaucoma	4.57e-05	0.000864	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CTSA—glaucoma	4.56e-05	0.000864	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	4.5e-05	0.000851	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—C3—glaucoma	4.45e-05	0.000843	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTT1—glaucoma	4.45e-05	0.000841	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—OPN4—glaucoma	4.37e-05	0.000828	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CA2—glaucoma	4.31e-05	0.000816	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NTRK2—glaucoma	4.18e-05	0.000791	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	3.98e-05	0.000754	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—OPN4—glaucoma	3.97e-05	0.000752	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PTGFR—glaucoma	3.94e-05	0.000745	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—FAS—glaucoma	3.84e-05	0.000727	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—glaucoma	3.81e-05	0.000721	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TXN—glaucoma	3.59e-05	0.000679	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NGFR—glaucoma	3.58e-05	0.000678	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTGFR—glaucoma	3.58e-05	0.000677	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP1B1—glaucoma	3.54e-05	0.00067	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SMO—glaucoma	3.51e-05	0.000665	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP1B1—glaucoma	3.49e-05	0.000661	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NTRK1—glaucoma	3.41e-05	0.000645	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LRP12—glaucoma	3.39e-05	0.000641	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—C3—glaucoma	3.34e-05	0.000633	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—glaucoma	3.27e-05	0.000618	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN2B—glaucoma	3.14e-05	0.000594	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA5A—glaucoma	3.12e-05	0.00059	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NARFL—glaucoma	3.12e-05	0.00059	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	3.04e-05	0.000576	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TXN—glaucoma	3.04e-05	0.000575	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EDN1—glaucoma	3.01e-05	0.00057	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTM1—glaucoma	2.83e-05	0.000536	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	2.79e-05	0.000529	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTT1—glaucoma	2.78e-05	0.000527	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NGF—glaucoma	2.77e-05	0.000524	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CA1—glaucoma	2.71e-05	0.000514	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	2.66e-05	0.000503	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—C3—glaucoma	2.63e-05	0.000498	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CTSA—glaucoma	2.63e-05	0.000497	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CA2—glaucoma	2.48e-05	0.00047	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APOE—glaucoma	2.45e-05	0.000464	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CAV1—glaucoma	2.43e-05	0.000459	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTT1—glaucoma	2.35e-05	0.000446	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—glaucoma	2.35e-05	0.000445	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OPN4—glaucoma	2.35e-05	0.000444	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—EDN1—glaucoma	2.32e-05	0.000438	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FN1—glaucoma	2.31e-05	0.000437	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—BAD—glaucoma	2.28e-05	0.000432	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP1B1—glaucoma	2.22e-05	0.00042	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCA1—glaucoma	2.22e-05	0.00042	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HEYL—glaucoma	2.18e-05	0.000413	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTGFR—glaucoma	2.11e-05	0.0004	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—C3—glaucoma	2.02e-05	0.000383	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCA1—glaucoma	1.88e-05	0.000355	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1B1—glaucoma	1.88e-05	0.000355	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOS3—glaucoma	1.83e-05	0.000347	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SMO—glaucoma	1.8e-05	0.000341	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—glaucoma	1.77e-05	0.000336	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TXN—glaucoma	1.75e-05	0.000331	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RPTOR—glaucoma	1.65e-05	0.000313	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NCK2—glaucoma	1.6e-05	0.000303	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1B—glaucoma	1.59e-05	0.000301	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—glaucoma	1.57e-05	0.000297	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA1—glaucoma	1.52e-05	0.000288	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—glaucoma	1.5e-05	0.000284	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CTSA—glaucoma	1.47e-05	0.000279	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—glaucoma	1.47e-05	0.000279	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—glaucoma	1.46e-05	0.000276	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CAV1—glaucoma	1.45e-05	0.000274	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—glaucoma	1.44e-05	0.000272	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA2—glaucoma	1.39e-05	0.000263	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC9—glaucoma	1.36e-05	0.000258	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—glaucoma	1.36e-05	0.000257	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—glaucoma	1.33e-05	0.000251	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—glaucoma	1.32e-05	0.00025	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—glaucoma	1.31e-05	0.000248	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—glaucoma	1.23e-05	0.000234	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAV1—glaucoma	1.22e-05	0.000231	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—glaucoma	1.19e-05	0.000225	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—C3—glaucoma	1.14e-05	0.000216	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NOS3—glaucoma	1.09e-05	0.000207	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCA1—glaucoma	1.08e-05	0.000204	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1B1—glaucoma	1.08e-05	0.000204	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMO—glaucoma	1.07e-05	0.000202	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—C3—glaucoma	1.04e-05	0.000197	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—glaucoma	9.99e-06	0.000189	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—glaucoma	9.99e-06	0.000189	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TXN—glaucoma	9.81e-06	0.000186	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTRK2—glaucoma	9.74e-06	0.000184	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NOS3—glaucoma	9.25e-06	0.000175	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—glaucoma	8.64e-06	0.000163	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—glaucoma	8.46e-06	0.00016	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGFR—glaucoma	8.36e-06	0.000158	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTRK1—glaucoma	7.94e-06	0.00015	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—glaucoma	7.63e-06	0.000144	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—glaucoma	7.6e-06	0.000144	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—glaucoma	7.32e-06	0.000139	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—glaucoma	7.11e-06	0.000134	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAV1—glaucoma	7.04e-06	0.000133	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—glaucoma	7.02e-06	0.000133	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGF—glaucoma	6.45e-06	0.000122	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—C3—glaucoma	6.14e-06	0.000116	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCA1—glaucoma	6.06e-06	0.000115	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1B1—glaucoma	6.06e-06	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—glaucoma	5.71e-06	0.000108	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CAV1—glaucoma	5.66e-06	0.000107	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FN1—glaucoma	5.39e-06	0.000102	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NOS3—glaucoma	5.32e-06	0.000101	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BAD—glaucoma	5.32e-06	0.000101	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—glaucoma	4.87e-06	9.21e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—glaucoma	4.84e-06	9.17e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—glaucoma	4.28e-06	8.1e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOS3—glaucoma	4.28e-06	8.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—glaucoma	3.98e-06	7.54e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAV1—glaucoma	3.95e-06	7.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—glaucoma	3.71e-06	7.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—glaucoma	3.43e-06	6.5e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—glaucoma	3.08e-06	5.83e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NOS3—glaucoma	2.99e-06	5.65e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—glaucoma	2.73e-06	5.17e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—glaucoma	2.33e-06	4.41e-05	CbGpPWpGaD
